Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Spinal Cord Injury Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Spinal Cord Injury Overview | 14 | 1 |
| Pipeline Products for Spinal Cord Injury Comparative Analysis | 15 | 1 |
| Spinal Cord Injury Therapeutics under Development by Companies | 16 | 3 |
| Spinal Cord Injury Therapeutics under Investigation by Universities/Institutes | 19 | 1 |
| Spinal Cord Injury Pipeline Products Glance | 20 | 3 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Spinal Cord Injury Products under Development by Companies | 23 | 3 |
| Spinal Cord Injury Products under Investigation by Universities/Institutes | 26 | 1 |
| Spinal Cord Injury Companies Involved in Therapeutics Development | 27 | 32 |
| AbbVie Inc | 27 | 1 |
| Acorda Therapeutics Inc | 28 | 1 |
| Asterias Biotherapeutics, Inc. | 29 | 1 |
| Asubio Pharma Co Ltd | 30 | 1 |
| Athersys Inc | 31 | 1 |
| BioArctic Neuroscience AB | 32 | 1 |
| BioAxone BioSciences Inc | 33 | 1 |
| Genervon Biopharmaceuticals LLC | 34 | 1 |
| Histocell SL | 35 | 1 |
| Kadimastem Ltd | 36 | 1 |
| Kringle Pharma Inc | 37 | 1 |
| Lpath Inc | 38 | 1 |
| MandalMed Inc | 39 | 1 |
| Mapreg SAS | 40 | 1 |
| Medgenics Inc | 41 | 1 |
| Neuralstem Inc | 42 | 1 |
| Neuronax SAS | 43 | 1 |
| New World Laboratories Inc | 44 | 1 |
| Omeros Corp | 45 | 1 |
| PharmatrophiX, Inc. | 46 | 1 |
| Pharmicell Co Ltd | 47 | 1 |
| Protagenic Therapeutics Inc. | 48 | 1 |
| Q Therapeutics Inc | 49 | 1 |
| Remedy Pharmaceuticals Inc | 50 | 1 |
| RespireRx Pharmaceuticals Inc | 51 | 1 |
| SanBio Inc | 52 | 1 |
| Stemedica Cell Technologies Inc | 53 | 1 |
| TissueGene Inc | 54 | 1 |
| TRB Chemedica International SA | 55 | 1 |
| Tumorend LLC | 56 | 1 |
| Vertex Pharmaceuticals Inc | 57 | 1 |
| Vicore Pharma AB | 58 | 1 |
| Spinal Cord Injury Therapeutics Assessment | 59 | 12 |
| Assessment by Monotherapy Products | 59 | 1 |
| Assessment by Combination Products | 60 | 1 |
| Assessment by Target | 61 | 3 |
| Assessment by Mechanism of Action | 64 | 3 |
| Assessment by Route of Administration | 67 | 2 |
| Assessment by Molecule Type | 69 | 2 |
| Drug Profiles | 71 | 102 |
| (buspirone + carbidopa + levodopa) Drug Profile | 71 | 1 |
| ABT-555 Drug Profile | 72 | 1 |
| AP-325 Drug Profile | 73 | 1 |
| APO-1 Drug Profile | 74 | 1 |
| ASTOPC-1 Drug Profile | 75 | 6 |
| AX-007 Drug Profile | 81 | 1 |
| BA-277 Drug Profile | 82 | 1 |
| BA-434 Drug Profile | 83 | 1 |
| C-21 Drug Profile | 84 | 2 |
| Cell Therapy for Spinal Cord Injury Drug Profile | 86 | 1 |
| Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury Drug Profile | 87 | 1 |
| Cellgram-SCI Drug Profile | 88 | 1 |
| CHEC-7 Drug Profile | 89 | 1 |
| CHEC-9 Drug Profile | 90 | 1 |
| chondroitinase ABC nanosphere Drug Profile | 91 | 1 |
| CLR-01 Drug Profile | 92 | 1 |
| CM-101 Drug Profile | 93 | 1 |
| CX-717 Drug Profile | 94 | 2 |
| Drug for Spinal Cord Injury Drug Profile | 96 | 1 |
| FAB-117HC Drug Profile | 97 | 1 |
| Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases Drug Profile | 98 | 1 |
| glyburide Drug Profile | 99 | 3 |
| GM-603 Drug Profile | 102 | 1 |
| HBN-1 Drug Profile | 103 | 1 |
| ICCN-100 Drug Profile | 104 | 1 |
| IMS-001 Drug Profile | 105 | 1 |
| IMS-002 Drug Profile | 106 | 1 |
| JM-4 Drug Profile | 107 | 1 |
| KP-100IT Drug Profile | 108 | 2 |
| LM11A-31BHS Drug Profile | 110 | 2 |
| LPA-181 Drug Profile | 112 | 1 |
| Lpathomab Drug Profile | 113 | 3 |
| MAP-4343 Drug Profile | 116 | 1 |
| Neu-2000 Drug Profile | 117 | 1 |
| NeuroRelease SCI Drug Profile | 118 | 1 |
| neurovitas Drug Profile | 119 | 1 |
| NOVO-117 Drug Profile | 120 | 1 |
| NSI-566 Drug Profile | 121 | 8 |
| NWL-53 Drug Profile | 129 | 1 |
| NX-210 Drug Profile | 130 | 1 |
| Oligonucleotide for Central Nervous System and Metabolic Disorders Drug Profile | 131 | 1 |
| PF-05285401 Drug Profile | 132 | 10 |
| porcine GM1 ganglioside Drug Profile | 142 | 1 |
| PT-00114 Drug Profile | 143 | 1 |
| Q-Cells Drug Profile | 144 | 2 |
| Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury Drug Profile | 146 | 1 |
| Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury Drug Profile | 147 | 1 |
| SB-618 Drug Profile | 148 | 1 |
| SB-623 Drug Profile | 149 | 4 |
| SC-0806 Drug Profile | 153 | 1 |
| Small Molecule to Antagonize GPR17 for Central Nervous System Disorders Drug Profile | 154 | 1 |
| Small Molecules for Spinal Cord Injury Drug Profile | 155 | 1 |
| Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis Drug Profile | 156 | 1 |
| Stem Cell Therapy for Central Nervous System Disorders Drug Profile | 157 | 1 |
| Stem Cell Therapy for CNS Disorders Drug Profile | 158 | 1 |
| Stem Cell Therapy for Neurodegenerative Diseases Drug Profile | 159 | 2 |
| Stem Cell Therapy for Spinal Cord Injury Drug Profile | 161 | 1 |
| Stem Cell Therapy for Spinal Cord Injury Drug Profile | 162 | 1 |
| Stem Cell Therapy for Spinal Cord Injury Drug Profile | 163 | 1 |
| SUN-13837 Drug Profile | 164 | 1 |
| Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury Drug Profile | 165 | 1 |
| Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease Drug Profile | 166 | 1 |
| TG-N Drug Profile | 167 | 1 |
| UH-0113 Drug Profile | 168 | 1 |
| UH-0213 Drug Profile | 169 | 1 |
| VX-210 Drug Profile | 170 | 3 |
| Spinal Cord Injury Dormant Projects | 173 | 6 |
| Spinal Cord Injury Discontinued Products | 179 | 1 |
| Spinal Cord Injury Product Development Milestones | 180 | 11 |
| Featured News &Press Releases | 180 | 1 |
| Mar 18, 2016: PixarBio Announces USFDA OPD Submission of NeuroRelease SCI for Orphan Drug Designation for Spinal Cord Injury | 180 | 1 |
| Feb 16, 2016: Remedy Pharmaceuticals Announces FDA Orphan Drug Designation in Two CNS Indications | 180 | 1 |
| Jan 27, 2016: Neuralstem Presented Cell Therapy Update At Phacilitate Cell &Gene Therapy World Conference | 181 | 1 |
| Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial | 182 | 1 |
| Nov 19, 2015: Athersys MultiStem Promotes Recovery After Acute Spinal Cord Injury in Preclinical Study | 183 | 1 |
| Aug 18, 2015: Remedy Pharmaceuticals Initiates Phase 2A Study of CIRARA in Spinal Cord Injury | 184 | 1 |
| Oct 09, 2014: First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center | 184 | 1 |
| Apr 23, 2014: Discovery Scientists Receive NIH Funding for Spinal Cord Injury Therapy | 185 | 1 |
| Apr 16, 2014: Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego | 186 | 1 |
| Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries | 187 | 1 |
| Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries | 187 | 1 |
| Jul 08, 2013: Asubio Broadens Inclusion Criteria For Landmark Spinal Cord Injury Clinical Trial | 187 | 1 |
| May 28, 2013: Neuralstem's Cells Induce Improvement In Acute Spinal Cord Injury Rats, UCSD Study Shows | 188 | 1 |
| Jan 14, 2013: Neuralstem Receives FDA Approval To Commence Phase I Spinal Cord Injury Trial | 189 | 1 |
| Nov 15, 2012: Vicore Pharma Announces Publication Of Study Results Of C21 In Spinal Cord Injury In Journal Neurobiology Of Disease | 190 | 1 |
| Appendix | 191 | 2 |
| Methodology | 191 | 1 |
| Coverage | 191 | 1 |
| Secondary Research | 191 | 1 |
| Primary Research | 191 | 1 |
| Expert Panel Validation | 191 | 1 |
| Contact Us | 191 | 1 |
| Disclaimer | 192 | 1 |